Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics according to the treatment protocol group

From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients

  Placebo
(n = 18)
Active treatment
(n = 18)
p
Age (yrs) 57.9 ± 6.7 58.2 ± 8.0 0.910
Males 14 (77.8) 13 (72.2) 0.700
Height (cm) 170.0 ± 9.2 170.2 ± 8.6 0.955
Weight (kg) 75.9 ± 11.0 80.2 ± 15.7 0.351
Body Mass Index (kg/m2) 26.3 ± 3.1 27.7 ± 2.8 0.161
SBP (mmHg) 133.3 ± 16.9 135.6 ± 13.5 0.666
DBP (mmHg) 84.1 ± 12.3 85.8 ± 9.1 0.636
Heart rate (bpm) 68.8 ± 6.8 66.4 ± 7.9 0.350
Total cholesterol (mg/dl) 198.2 ± 23.7 201.9 ± 27.5 0.667
HDL cholesterol (mg/dl) 47.6 ± 7.9 51.3 ± 7.2 0.144
LDL cholesterol (mg/dl) 129.2 ± 26.1 126.7 ± 30.4 0.789
Triglycerides (mg/dl) 107.1 ± 34.8 119.5 ± 27.9 0.245
Uric acid (mg/dl) 5.8 ± 1.1 5.4 ± 0.8 0.175
Serum creatinine (mg/dl) 0.94 ± 0.14 0.99 ± 0.20 0.402
Glycaemia (mg/dl) 95.7 ± 11.2 93.1 ± 7.5 0.407
MoCA test ES 1.94 ± 0.94 1.89 ± 1.08 0.870
Word Match Testing ES 2.00 ± 0.97 2.50 ± 1.20 0.178
Stroop test E ES 2.22 ± 0.88 1.67 ± 1.65 0.215
Stroop test T ES 2.67 ± 0.91 2.28 ± 1.67 0.392
EQ-VAS 65.3 ± 12.8 68.1 ± 12.8 0.520
Augmentation Index (%) 14.19 ± 10.00 18.59 ± 18.21 0.400
Antihypertensive therapy    
 ACE-inhibitors 2 (11.1) 2 (11.1) 1.000
 ATII receptor blockers 13 (72.2) 14 (77.8) 0.700
 Beta-blockers 4 (22.2) 5 (27.8) 0.700
 Calcium channel antagonists 7 (38.9) 6 (33.6) 0.729
 Diuretics 9 (50.0) 9 (50.0) 1.000
  1. Values are numbers (percentage) or means ± standard deviation
  2. SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MoCa = Montreal Cognitive Assessment; ES = equivalent score; EQ-VAS = EQ-5D test visual analogue scale